Transplant drug tweak may tame common virus

NCT ID NCT07570433

Not yet recruiting Disease control Sponsor: Oriol Manuel Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adjusting the dose of anti-rejection drugs can help control CMV infection in organ transplant recipients. About 100 adults who have had a kidney, liver, heart, lung, or pancreas transplant and now have a CMV infection will take part. Researchers will monitor how the virus levels change and use immune system tests to guide treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CMV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection Infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CMV INFECTION

Contacts and locations

Locations

Centre hospitalier universitaire Bordeaux (CHU Bordeaux)

Bourdeaux, Talence Cedex, 33404, France
Centre hospitalier universitaire Toulouse (CHU Toulouse)

Toulouse, Toulouse, 31059, France
Centre hospitalier universitaire vaudois (CHUV)

Lausanne, Canton of Vaud, 1011, Switzerland
Hospital Universitari Vall D'Hebron

Barcelona, Catalonia, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.